Recently, a novel FGFR2 inhibitor called bemarituzumab, which is an IgG2 monoclonal antibody that targets FGFR2b, showed promising results in GC patients with FGFR2 gene amplification in a phase II clinical trial (FIGHT trial) [38]. Here, FGFR2 is linked to gastric cancer.